MA71255A - Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 - Google Patents
Composés pour le traitement de l'ataxie spinocérébelleuse de type 3Info
- Publication number
- MA71255A MA71255A MA71255A MA71255A MA71255A MA 71255 A MA71255 A MA 71255A MA 71255 A MA71255 A MA 71255A MA 71255 A MA71255 A MA 71255A MA 71255 A MA71255 A MA 71255A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- treatment
- spinocerebellar ataxia
- ataxia type
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263354339P | 2022-06-22 | 2022-06-22 | |
| PCT/US2023/068717 WO2023250316A1 (fr) | 2022-06-22 | 2023-06-20 | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 |
| EP23827977.2A EP4543444A4 (fr) | 2022-06-22 | 2023-06-20 | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71255A true MA71255A (fr) | 2025-04-30 |
Family
ID=89380638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71255A MA71255A (fr) | 2022-06-22 | 2023-06-20 | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250382305A1 (fr) |
| EP (1) | EP4543444A4 (fr) |
| JP (1) | JP2025521545A (fr) |
| KR (1) | KR20250035623A (fr) |
| CN (1) | CN119997954A (fr) |
| AU (1) | AU2023289366A1 (fr) |
| CA (1) | CA3259536A1 (fr) |
| CL (1) | CL2024003939A1 (fr) |
| CO (1) | CO2024017547A2 (fr) |
| CR (1) | CR20240567A (fr) |
| IL (1) | IL317705A (fr) |
| MA (1) | MA71255A (fr) |
| MX (1) | MX2024015863A (fr) |
| PE (1) | PE20250836A1 (fr) |
| WO (1) | WO2023250316A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108519TA (en) | 2019-02-13 | 2021-09-29 | Ptc Therapeutics Inc | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
| WO2020167624A1 (fr) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Composés de pyrrolo[2,3-d] pyrimidine pour le traitement de la dysautonomie familiale |
| WO2026019945A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019918A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019928A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019917A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019936A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019931A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019930A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019893A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019914A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019950A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
| WO2026019946A1 (fr) * | 2024-07-17 | 2026-01-22 | Skyhawk Therapeutics, Inc. | Compositions utiles pour moduler l'épissage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0912245A2 (pt) * | 2008-03-05 | 2019-09-24 | Takeda Pharmaceuticals Co | composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto |
| WO2012044993A1 (fr) * | 2010-09-30 | 2012-04-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Composés, compositions pharmaceutiques, et procédés de traitement ou de prévention de maladies ou de troubles neurodégénératifs |
| MA39987A (fr) * | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| SG11202108519TA (en) * | 2019-02-13 | 2021-09-29 | Ptc Therapeutics Inc | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
| EP3929185A4 (fr) * | 2019-02-19 | 2023-02-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Composé cyclique condensé contenant de l'azote, son procédé de préparation et son utilisation |
-
2023
- 2023-06-20 MA MA71255A patent/MA71255A/fr unknown
- 2023-06-20 PE PE2024003069A patent/PE20250836A1/es unknown
- 2023-06-20 CR CR20240567A patent/CR20240567A/es unknown
- 2023-06-20 WO PCT/US2023/068717 patent/WO2023250316A1/fr not_active Ceased
- 2023-06-20 EP EP23827977.2A patent/EP4543444A4/fr active Pending
- 2023-06-20 AU AU2023289366A patent/AU2023289366A1/en active Pending
- 2023-06-20 IL IL317705A patent/IL317705A/en unknown
- 2023-06-20 CN CN202380060030.9A patent/CN119997954A/zh active Pending
- 2023-06-20 JP JP2024575231A patent/JP2025521545A/ja active Pending
- 2023-06-20 CA CA3259536A patent/CA3259536A1/fr active Pending
- 2023-06-20 US US18/877,505 patent/US20250382305A1/en active Pending
- 2023-06-20 KR KR1020247042593A patent/KR20250035623A/ko active Pending
-
2024
- 2024-12-17 MX MX2024015863A patent/MX2024015863A/es unknown
- 2024-12-19 CL CL2024003939A patent/CL2024003939A1/es unknown
- 2024-12-20 CO CONC2024/0017547A patent/CO2024017547A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023289366A1 (en) | 2025-01-23 |
| IL317705A (en) | 2025-02-01 |
| JP2025521545A (ja) | 2025-07-10 |
| US20250382305A1 (en) | 2025-12-18 |
| CN119997954A (zh) | 2025-05-13 |
| CO2024017547A2 (es) | 2025-03-27 |
| EP4543444A1 (fr) | 2025-04-30 |
| CA3259536A1 (fr) | 2023-12-28 |
| KR20250035623A (ko) | 2025-03-12 |
| CL2024003939A1 (es) | 2025-05-02 |
| WO2023250316A1 (fr) | 2023-12-28 |
| MX2024015863A (es) | 2025-04-02 |
| CR20240567A (es) | 2025-03-03 |
| EP4543444A4 (fr) | 2026-04-29 |
| PE20250836A1 (es) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA71255A (fr) | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 | |
| EP4288059A4 (fr) | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 | |
| EP4301359A4 (fr) | Composés de liaison covalents pour le traitement d'une maladie | |
| EP4288441A4 (fr) | Procédés de traitement de l'ataxie spinocérébelleuse de type 3 | |
| EP3986863A4 (fr) | Inhibiteurs de glycolate oxydase pour le traitement d'une maladie | |
| EP3755804A4 (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
| EP3927705A4 (fr) | Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles neurodégénératifs | |
| MA55973A (fr) | Composé pour le traitement de la goutte ou de l'hyperuricémie | |
| EP3986409A4 (fr) | Inhibiteurs de l'uridine phosphorylase (upase) pour le traitement de pathologies hépatiques | |
| EP4192453A4 (fr) | Utilisation de dexpramipexole pour le traitement de l'asthme modéré à sévère | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| EP4301132A4 (fr) | Inhibiteur de rock2 pour le traitement d'une infection virale | |
| EP4200402A4 (fr) | Développement de nouvelles thérapies géniques pour traiter la perte osseuse due à l'inflammation | |
| EP4232075A4 (fr) | Composés, compositions et méthodes d'utilisation pour le traitement de spondylodèses | |
| EP3931178A4 (fr) | Composés pour la prévention et le traitement d'un dysfonctionnement cognitif post-opératoire | |
| EP3883552A4 (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP4274583A4 (fr) | Procédés et composés destinés au traitement de l'ataxie de friedreich | |
| EP4121403A4 (fr) | Composés nitro-aminoadamantane pour le traitement d'infections par le bêtacoronavirus | |
| EP4181915A4 (fr) | Compositions pour le traitement de l'obésité | |
| EP3996729C0 (fr) | Composition pour la prévention ou le traitement de la dépression ou de l'anxiété | |
| EP4143218A4 (fr) | Composés pour la prévention et le traitement d'un dysfonctionnement cognitif de soins post-intensifs et d'un dysfonctionnement cognitif résultant d'une détresse respiratoire | |
| EP4149469A4 (fr) | Utilisation de composés pour le traitement d'infections virales | |
| EP4288054A4 (fr) | Procédés de traitement de l'ataxie spinocérébelleuse de type 3 | |
| EP3826633A4 (fr) | Compositions pour le traitement de l'hypertension |